Main
About
Mission
Leadership
Board of Directors
Scientific Advisory Board
Contact us
Pharma.ai
Pharma.ai Suite
PandaOmics
Generative Biologics
Chemistry42
inClinico
Science42: DORA
PandaOmics Box
Pipeline
News & Media
Press Releases
Blog
Media Coverage
Publications
Media Kit
Careers
Docuthon
PreciousGPT
Nach01
Sustainability
EN
_
FR
Main
About
Mission
Leadership
Board of Directors
Scientific Advisory Board
Contact us
Pharma.ai
Pharma.ai Suite
PandaOmics
Generative Biologics
Chemistry42
inClinico
Science42: DORA
PandaOmics Box
Pipeline
News & Media
Press Releases
Blog
Media Coverage
Publications
Media Kit
Careers
Docuthon
PreciousGPT
Nach01
Sustainability
Press Releases
2023
Insilico announces the expansion of its oncology pipelines and delivers the new generation FGFR2/3 inhibitor
28 December 2023
Insilico announces the second generation DGKA inhibitor for the treatment of PD-1/PD-L1 resistance solid tumors
26 December 2023
Insilico Medicine leadership to attend 42nd Annual J.P. Morgan Healthcare Conference
18 December 2023
Insilico Medicine announces AI drug discovery milestone achievement in pharma collaboration
12 December 2023
In 7 months, online Target ID course from AI drug discovery company Insilico Medicine surpasses 2,500 users
11 December 2023
Insilico Medicine announces first-in-human study for oral PHD 1/2 inhibitor ISM5411 for inflammatory bowel disease (IBD)
7 December 2023
Insilico Medicine showcases latest AI drug discovery platform breakthroughs
29 November 2023
International team uses AI platform to find dual targets for aging and cancer
16 November 2023
Insilico Medicine presents at Future Investment Initiative Conference in Riyadh
20 October 2023
Insilico Medicine nominates novel CDK12/13 small molecule inhibitor as preclinical candidate for multiple tumors
17 October 2023
Insilico Medicine presents data on AI-designed cancer drugs at 3 major cancer conferences
16 October 2023
Insilico Medicine founder and CEO Alex Zhavoronkov, Ph.D., to present on AI drug discovery at LSX Nordic Congress
5 October 2023
Insilico Medicine discovers novel dual targets for aging and disease using Microsoft BioGPT
27 September 2023
Insilico Medicine and University of Cambridge present new approach to discover targets for Alzheimer's and other diseases with protein phase separation
25 September 2023
Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor
12 September 2023
Global Entanglement: Insilico Medicine presents at Morgan Stanley Global Healthcare Conferences in the U.S. and Asia
5 September 2023
World's largest aging research and drug discovery conference celebrates 10 years
23 August 2023
Insilico advances anti-tumor drug to Phase I, marking first clinical milestone in Fosun Pharma collaboration
15 August 2023
Insilico Medicine joins Montreal Chamber of Commerce to drive continued innovation
8 August 2023
After 7 years, generative AI succeeds in predicting clinical trial outcomes
3 August 2023
Insilico Medicine leverages generative AI and AlphaFold structures for novel cancer drug
2 August 2023
AI drives new era of target identification and drug design
1 August 2023
Michael Bayewitch, PhD named Head of BD and Licensing North America for Insilico Medicine
28 July 2023
Insilico Medicine nominates preclinical candidate of inhalation solution for ISM001-055, the first generative AI IPF drug
20 July 2023
Insilico Medicine scientists propose stricter standards for evaluating generative AI-produced molecules
18 July 2023
Scientists use Insilico Medicine's generative AI platform to predict drug targets for rare lysosomal storage disease
14 July 2023
Emerging tech storyteller Taryn Southern announced as Docuthon judge
11 July 2023
Insilico Medicine appoints Sujata Rao, MD as Chief Medical Officer
29 June 2023
First drug discovered and designed with generative AI enters Phase II trials, with first patients dosed
27 June 2023
Insilico Medicine's transformer-based aging clock provides insights into aging, disease, and new therapeutic targets
15 June 2023
Insilico Medicine announces potential best-in-class pan-TEAD inhibitor candidate ISM6331 targeting advanced solid tumors
8 June 2023
Insilico Medicine Founder and CEO Alex Zhavoronkov, PhD presents at Jefferies Global Healthcare Conference
7 June 2023
Insilico Medicine receives IND approval for novel AI-designed USP1 inhibitor for cancer
25 MAY 2023
Insilico Medicine founder and CEO Alex Zhavoronkov, Ph.D., presents on AI Drug Discovery for NIH National Institute on Drug Abuse
23 MAY 2023
Insilico Medicine-led study combines quantum computing and generative AI for drug discovery
19 MAY 2023
Insilico Medicine delivers preclinical candidate targeting ENPP1 for cancer immunotherapy and the treatment of rare disease using generative AI
18 MAY 2023
Insilico Medicine founder and CEO Alex Zhavoronkov, PhD, presents at Asia Summit on Global Health
16 MAY 2023
Insilico Medicine appoints Michael Bayewitch as VP, Business Development and Strategy
15 MAY 2023
Insilico Medicine founder and CEO to give keynote on disease modeling with AI at PEGS Boston
11 MAY 2023
AI drug discovery company Insilico Medicine offers free course on target identification
10 MAY 2023
Head of Insilico Medicine's Hong Kong Office to give keynote on AI drug discovery at HKUST Big Data Institute
4 MAY 2023
High school student researchers find new brain tumor drug targets using AI
2 MAY 2023
Insilico Medicine founder and CEO Alex Zhavoronkov, Ph.D., presents at LSX World Congress
28 APRIL 2023
Insilico Medicine successfully discovered potent, selective, and orally bioavailable small-molecule inhibitor of CDK8 using generative AI
12 APRIL 2023
Insilico Medicine presents four posters featuring AI-designed anti-cancer drugs at AACR
4 APRIL 2023
Using AI to address aging and disease: Insilico Medicine's Alex Zhavoronkov, PhD presents at the Geroscience Summit
3 APRIL 2023
Insilico Medicine featured in BBC-produced series on biotech breakthroughs
29 MARCH 2023
Insilico Medicine brings AI-powered "ChatPandaGPT" to its target discovery platform
13 MARCH 2023
Generative AI for drug discovery expert Alex Zhavoronkov, Ph.D. presents at NextMed Health March 14
10 MARCH 2023
Insilico Medicine's Generative AI Pioneer Alex Zhavoronkov, PhD at Lab of the Future March 9
1 MARCH 2023
Insilico Medicine sends first generative AI-designed drug for COVID-19 and variants to clinic
23-FEBRUARY-2023
Tech journalist and filmmaker Amelia Martyn-Hemphill announced as Docuthon judge
21-FEBRUARY-2023
Emmy Award-winning filmmaker Oren Rosenfeld joins Insilico Medicine's Docuthon as judge
9-FEBRUARY-2023
Insilico Medicine receives FDA Orphan Drug Designation for generative AI discovered and designed drug for idiopathic pulmonary fibrosis
8-FEBRUARY-2023
New paper explores Insilico Medicine's generative AI drug design platform Chemistry42
7-FEBRUARY-2023
Insilico Medicine opens largest AI-powered biotechnology research center in the Middle East
1-FEBRUARY-2023
New study uses AlphaFold and AI to accelerate design of novel drug for liver cancer
19-JANUARY-2023
Insilico Medicine announces positive topline results of the New Zealand Phase 1 trial of INS018_055, an AI-designed drug for an AI-discovered target
10-JANUARY-2023
2022
Insilico Medicine nominates potential first-in-class preclinical candidate with novel AI-designed structure for novel AI-discovered target in immuno-oncology
20-DECEMBER-2022
Read
Insilico Medicine Awarded Over $700,000 to Design New Contraceptive Options with AI
16-NOVEMBER-2022
Read
Insilico Medicine receives Company of the Year Award at BioCentury-BayHelix East-West Summit
16-NOVEMBER-2022
Read
Insilico Medicine Signs Strategic Research Collaboration with Sanofi worth up to $1.2 Billion
8-NOVEMBER-2022
Read
Deepfake Technology in Drug Design. Insilico Medicine unveils its fully updated Pharma.AI platform in virtual event
20-OCTOBER-2022
Read
Saudi Ministry of Investment and Insilico Medicine sign agreement to expand region's biotechnology capabilities
10-SEPTEMBER-2022
Read
Insilico Medicine Announces New Investment Led by Aramco-backed Prosperity7 Ventures, bringing total Series D Financing to $95 Million
10-AUGUST-2022
Read
Insilico Medicine identified multiple new targets for amyotrophic lateral sclerosis (ALS) using its AI-driven target discovery engine
07-JULY-2022
Read
Insilico Medicine appoints Dr. Feng Ren as co-CEO
16-JUNE-2022
Read
Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Robotics Laboratory
06-JUNE-2022
Read
Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment
24-MAY-2022
Read
CB Insights Again Names Insilico Medicine One of the Top 100 AI Companies in the World
17-MAY-2022
Read
Insilico Medicine expands synthetic lethality portfolio with nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers
05-MAY-2022
Read
Insilico Medicine Announces Advancement of Its Preclinical Candidate for USP1 Synthetic Lethality Target to IND-enabling Studies for Various Oncological Disorders
13-APR-2022
Read
Insilico Medicine Applauded by Frost & Sullivan for Enabling Rapid and Cost-Effective Drug Discovery and Development with Its Pharma.AI Platform
25-JAN-2022
Read
Fosun Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets
11-JAN-2022
Read
Insilico Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference
06-JAN-2022
Read
Insilico Medicine Announces the Nomination of Two Preclinical Candidates for PHD2, 12 Months After Program Initiation
05-JAN-2022
Read
2021
Insilico Medicine Appoints Business Leader, Michelle Chen, as Chief Business Officer
19-OCT-2021
Read
Insilico Medicine Appoints Nirav Jhaveri as Chief Financial Officer
23-SEP-2021
Read
PAQ Therapeutics Announces Collaboration with Insilico Medicine to Develop Novel Therapies through Autophagy-Dependent Degradation
09-SEP-2021
Read
Huadong Medicine and Insilico Medicine enter co-development partnership to advance oncology drug discovery by hitting undruggable targets
08-SEP-2021
Read
Insilico Medicine and University of Cambridge Announce a Collaboration on Target Identification for Human Diseases Linked to Protein Liquid-liquid Phase Separation
07-SEP-2021
Read
Insilico Medicine Appoints Dr. Robert Spiegel, MD, FACP, as acting Chief Medical Officer (CMO) to Oversee the Clinical Translation of its Preclinical Pipeline Assets
02-SEP-2021
Read
Insilico Medicine Collaborates with Gray Matter to Fight Age-related Cognitive Decline
01-SEP-2021
Read
Insilico Medicine and 4B Technologies Announce Strategic Collaboration in Advancing Novel Drug Discovery for Neurodegenerative Diseases
27-AUG-2021
Read
The Former Director of the Center for Drug Evaluation and Research at FDA and R&D Leader at Amgen, Steven Galson Joins Insilico Medicine as Independent Director
11-AUG-2021
Read
Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas
9-AUG-2021
Read
Insilico Medicine Announces the Preclinical Candidate for Kidney Fibrosis Discovered Using End-to-End Artificial Intelligence Engine
4-AUG-2021
Read
Insilico Medicine and Westlake Pharma Announce Cooperation Relationship on Accelerating the Innovative Drugs R&D for Novel Coronavirus
3-AUG-2021
Read
GenFleet Therapeutics and Insilico Medicine Announce Strategic Partnership
20-JUL-2021
Read
Insilico Medicine Raises $255 Million in Series C Financing Led by Warburg Pincus
22-JUN-2021
Read
Insilico collaborates with Teva on AI system for target discovery
22-JUN-2021
Read
The Indiana Biosciences Research Institute deploys Insilico PandaOmics AI for target discovery
9-JUN-2021
Read
AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine
25-MAR-2021
Read
Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs
09-MAR-2021
Read
Insilico Medicine Achieves Industry First Nominating Preclinical Candidate Discovered by AI
24-FEB-2021
Read
Syngenta Crop Protection and Insilico Medicine to Harness Artificial Intelligence to Transform Sustainable Product Innovation
03-FEB-2021
Read
2020
Insilico partners with APRINOIA on AI-powered neurodegenerative drug discovery
29-DEC-2020
Read
Imagining perfect molecules using AI - a benchmarking system for generative chemistry
30-NOV-2020
Read
Merck KGaA, Darmstadt, Germany to deploy Insilico Medicine's Chemistry42 AI platform
17-NOV-2020
Read
Insilico announces a multi-target AI-powered drug discovery collaboration with Janssen
10-NOV-2020
Read
Insilico partners with Taisho on end-to-end AI-powered senolytic drug discovery
15-OCT-2020
Read
Insilico announces the launch of AI-powered COVIDomic to support COVID-19 research worldwide
8-SEP-2020
Read
International team identifies a new regulatory pathway in bladder cancer
20-AUG-2020
Read
Insilico Medicine and Arctoris to collaborate on COVID-19 by combining robotics and AI
9-JUL-2020
Read
Can your gut microbes tell you how old you really are?
11-JUN-2020
Read
Scientists use machine learning to predict major clinical forms of drug cardiotoxicity
9-JUN-2020
Read
Scientists Use Virtual Reality to Refine New AI-Generated Drugs for COVID-19
21-MAY-2020
Read
New artificial intelligence model to bridge biology and chemistry
19-MAY-2020
Read
Frost & Sullivan recognizes Insilico as innovation leader in drug discovery
30-APR-2020
Read
Insilico and Astellas collaborate on AI for a conventionally challenging target family
27-APR-2020
Read
Insilico collaborates with Boehringer Ingelheim on AI system for target discovery
14-APR-2020
Read
Beijing Tide Pharmaceutical and Insilico Medicine enter into an agreement for cancer therapy
16-MAR-2020
Read
FierceMedTech names Insilico Medicine as one of its 'Fierce 15' companies of 2019
9-MAR-2020
Read
MIT Technology Review selects AI molecular design as a breakthrough and highlights Insilico
26-FEB-2020
Read
AI preclinical research program targeting brain cancers starts at Insilico Medicine
26-FEB-2020
Read
Insilico collaborates with Pfizer on novel data and AI system for target discovery
14-JAN-2020
Read
Insilico Medicine publishes molecular structures for the key protein target of 2019-nCoV
6-FEB-2020
Read
Beiersdorf and Insilico employ AI technology in computer-simulated skin research
8-JAN-2020
Read
Deep learning enables rapid identification of potent DDR1 kinase inhibitors
Read publication
Track the news on
Be the first to know our news!
Once a month you will learn about our latest features and hottest news.
And no spam of course.
Required Field
Please enter a valid email address
Please enter a valid name
Please enter a valid phone number
Value is too small
Subscribe
Required Field
Please enter a valid email address
Please enter a valid name
Please enter a valid phone number
Value is too small
By clicking the button you agree to our
Privacy Policy